Valuation: Theraclion

Market Cap 42.55M 46.65M 39.34M 35.5M 66.87M 4.36B 69.5M 475M 188M 2.35B 175M 171M 7.43B P/E 2026 *
-5.78x
P/E 2027 * -5.78x
Enterprise Value 46.05M 50.49M 42.58M 38.42M 72.37M 4.72B 75.22M 514M 203M 2.55B 189M 185M 8.04B EV / Sales 2026 *
35.4x
EV / Sales 2027 * 13.1x
Free-Float
32.52%
Yield 2026 *
-
Yield 2027 * -
1 day+0.34%
1 week-11.52%
Current month-16.57%
1 month+2.82%
3 months-8.75%
6 months+19.79%
Current year-2.99%
1 week 0.56
Extreme 0.555
0.66
1 month 0.51
Extreme 0.51
0.85
Current year 0.4
Extreme 0.402
0.93
1 year 0.4
Extreme 0.402
0.93
3 years 0.14
Extreme 0.1416
1.25
5 years 0.14
Extreme 0.1416
1.66
10 years 0.14
Extreme 0.1416
6.3
Manager TitleAgeSince
Chief Executive Officer - 23/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 21/06/2021
Director/Board Member - 27/01/2022
Director/Board Member - 28/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26 Exercice

Director

266,139 0.3627%
Change 5-day change 1-year change 3-year change Capi.($)
+0.34%-11.52%-13.35%+16.80% 46.87M
+0.47%-3.53%+20.20%+47.62% 254B
+1.08%-2.71%+1.51%+8.48% 159B
-1.16%-5.08%-22.08%+36.85% 149B
+1.53%-2.89%-55.83%-19.53% 62.37B
-0.57%-0.62%+25.12%+56.50% 60.62B
+1.25%+0.74%+5.46%-12.32% 53.05B
+2.33%-0.23%+22.73%+54.89% 48.55B
-4.08%-8.43%+1.96%+56.17% 46.7B
+3.37%-1.03%+23.74%+78.61% 44.21B
Average +0.53%-3.03%+0.95%+32.41% 88B
Weighted average by Cap. +0.44%-3.00%+3.03%+33.35%

Financials

2026 *2027 *
Net sales 1.3M 1.43M 1.2M 1.08M 2.04M 133M 2.12M 14.52M 5.74M 71.9M 5.35M 5.24M 227M 3.6M 3.95M 3.33M 3M 5.66M 369M 5.88M 40.2M 15.89M 199M 14.81M 14.5M 629M
Net income -6.3M -6.91M -5.82M -5.26M -9.9M -646M -10.29M -70.35M -27.81M -348M -25.92M -25.37M -1.1B -6.6M -7.24M -6.1M -5.51M -10.37M -676M -10.78M -73.7M -29.13M -365M -27.15M -26.58M -1.15B
Net Debt 3.5M 3.84M 3.24M 2.92M 5.5M 359M 5.72M 39.08M 15.45M 194M 14.4M 14.1M 611M 4.6M 5.04M 4.25M 3.84M 7.23M 471M 7.51M 51.37M 20.31M 254M 18.92M 18.53M 803M
Projected Income Statement - Annual - Theraclion
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36
Date Price Change Volume
18/11/26 €0.5840 +0.34% 14,660
17/11/26 €0.5820 +0.34% 37,220
16/11/26 €0.5800 -2.36% 67,171
13/11/26 €0.5940 -6.31% 220,776
12/11/26 €0.6340 -3.94% 41,234
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.6411USD
Average target price
2.230USD
Spread / Average Target
+247.83%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Theraclion
  1. Stock Market
  2. Stocks
  3. ALTHE Stock